Drug firm Lupin on Tuesday said it has launched generic Silodosin capsules, used for treatment of signs and symptoms of benign enlargement of the prostate gland, in the US market.
The company has launched its Silodosin capsules in the strengths of 4 mg and 8 mg after receiving an approval from the United States Food and Drug Administration (USFDA) earlier, the company said in a statement.
The company’s product is generic equivalent of Allergan’s Rapaflo capsules, it added.
As per IQVIA MAT September 2018 data, Rapaflo had annual sales of $198.5 million in the US, Lupin said.
The capsules are indicated for the treatment of the signs and symptoms of prostatic hyperplasia (BPH), it added.
Shares of Lupin today closed at ₹888.05, down 1.14 per cent on BSE.